Home / Stocks / ARQT

Arcutis Biotherapeutics (ARQT, Biotechnology) Stock Valuation & Fair Value No P/E valuation

Arcutis Biotherapeutics (ARQT, Biotechnology) trades at a blended P/E of 82.9, trading without a historical P/E to compare against, with a forward growth estimate above 100% and a PEG of 0.68. Analysts' one-year estimates have been hit 20% of the time.

This company has no P/E to compare against its own history, so tickerseer publishes no valuation rating for it. The figures below are unaffected.

DATA AS OF 2026-09-21
Blended P/E
82.9
Normal P/E
—
PEG
0.68
Fwd growth
>100%
Div yield
0.0%
RSI (14)
57.6
Neutral

The Street vs SeerForecast

Wall Street's mean price target for ARQT is $37.00 across 7 analysts, 40.3% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: we publish none, because it has no P/E to compare against its own history. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer has published no valuation rating since 2026-07-31, because this company has no P/E to compare against its own history.

Blended P/E and rating by weekBlended P/E moved from 439.7 to 82.9 between 2026-07-31 and 2026-09-21, with 1 rating change over 18 recorded weeks.2026-07-31: P/E 439.7, No P/E valuation (recalculated)2026-08-03: P/E 415.9, No P/E valuation2026-08-07: P/E 415.9, No P/E valuation (recalculated)2026-08-10: P/E 112.9, No P/E valuation2026-08-14: P/E 112.9, No P/E valuation (recalculated)2026-08-17: P/E 439.7, No P/E valuation2026-08-21: P/E 439.7, No P/E valuation (recalculated)2026-08-24: P/E 101.7, No P/E valuation2026-08-27: P/E 101.7, No P/E valuation (recalculated)2026-08-28: P/E 101.7, No P/E valuation (recalculated)2026-08-30: P/E 101.7, No P/E valuation (recalculated)2026-08-31: P/E 92.2, No P/E valuation2026-09-05: P/E 92.2, No P/E valuation (recalculated)2026-09-07: P/E 88.8, No P/E valuation2026-09-12: P/E 88.8, No P/E valuation (recalculated)2026-09-14: P/E 85.1, No P/E valuation2026-09-19: P/E 85.1, No P/E valuation (recalculated)2026-09-21: P/E 82.9, No P/E valuation100.0200.0300.0400.0Jul 31Aug 13Aug 26Sep 8Sep 21
Attractively valuedNo P/E valuationAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 439.7not availableNo P/E valuation
2026-09-21P/E 82.9not availableNo P/E valuation ← now

Frequently asked questions

Is Arcutis Biotherapeutics stock overvalued?

At a blended P/E of 82.9, Arcutis Biotherapeutics has no historical normal P/E on record to compare that against, with a PEG of 0.68 on forward growth above 100%. tickerseer therefore publishes no valuation rating for it.

What is Arcutis Biotherapeutics's fair value and PEG?

Arcutis Biotherapeutics trades at a blended P/E of 82.9, a PEG of 0.68, and a forward growth estimate above 100%.

Has tickerseer's rating of Arcutis Biotherapeutics changed?

tickerseer has published no valuation rating since 2026-07-31, because this company has no P/E to compare against its own history.

What is the analyst price target for Arcutis Biotherapeutics?

The mean Wall Street price target for Arcutis Biotherapeutics is $37.00 across 7 analysts, 40.3% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track ARQT free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.